Vitamin D and Colds: What Do the Large Meta-Analyses Show?

Few supplement claims get repeated as often as the idea that vitamin D "boosts immunity" and protects against colds. Nearly every health guide recommends it during autumn and winter, and pharmacies see a sales spike for vitamin D products at exactly that time. As we describe in more depth in our knowledge-base entry on vitamin D3, this vitamin does play a documented role in regulating immune response — acting on respiratory epithelial cells and immune cells alike, supporting the production of antimicrobial peptides.

The problem is that a biological mechanism alone says nothing about whether supplementation actually translates into fewer colds in real life — and if it does, at what dose and in what schedule. The answer given by two large meta-analyses of randomized trials is more nuanced than the popular slogan: the effect is real but modest, and depends heavily on exactly how vitamin D is dosed. That distinction — daily small doses versus infrequent large doses — turns out to be the single biggest factor determining whether supplementation works at all.

The starting point is a 2017 meta-analysis published in the BMJ, led by Adrian Martineau. This study stands out methodologically: rather than relying solely on pooled, averaged results as published in individual trials (aggregate data), the authors obtained individual participant data from 25 randomized trials and re-analyzed it as a single combined dataset. This method — individual participant data (IPD) meta-analysis — allows for far more precise detection of subgroup effects than a standard aggregate-data meta-analysis.

In other words: when the authors pooled all 25 trials into one overall result, a protective effect was visible, but modest (roughly a 12% risk reduction). Only breaking the result down by dosing schedule revealed that this modest overall figure was in fact hiding two very different pictures — real protection with regular dosing, and essentially no effect with large, infrequent bolus dosing.

The difference between daily and bolus dosing is not arbitrary and has a logical mechanistic explanation. A large, infrequent dose of vitamin D (e.g., once a month or once a quarter) causes a sharp spike in blood 25(OH)D concentration, followed by a gradual decline until the next dose — so the body spends most of the time either in a state of excess or approaching deficiency, with concentration never stable for long.

Daily or weekly dosing in smaller portions keeps blood vitamin D concentration relatively stable and predictable throughout the supplementation period. Since part of vitamin D's immunomodulatory action depends on maintaining an adequate concentration of its active form in tissues, including immune cells and respiratory epithelium, stability of concentration — not just its time-averaged value — appears to matter clinically. This explains why two people with the same "average" vitamin D level over a given period may have different infection risk if one takes doses daily and the other in infrequent boluses.

This distinction makes biological sense: supplementation in someone with a genuine deficiency replenishes a missing substrate needed for proper immune function, while in someone who already has sufficient vitamin D, additional supplementation has less to "fix" — so the marginal effect should logically be smaller. It's worth noting, though, that the effect did not disappear entirely even in the non-deficient group (an OR of 0.75 is still a meaningful risk reduction), so this isn't a simple "works or doesn't" situation depending on baseline level, but a gradation of effect size.

Science rarely settles on a single study, however large. In 2021, the same research group (the Martineau/Jolliffe group) published an updated meta-analysis in The Lancet Diabetes & Endocrinology, this time based on aggregate data from nearly twice as many trials as in 2017. This is an important test of whether the earlier conclusions would hold up in a much larger sample.

It's worth pausing on the fact that the weakened signal in the "baseline deficiency" subgroup between 2017 and 2021 is not a convenient omission in this article — it's a real finding described by the authors themselves in the update. The same researchers who reported a strong effect in deficient individuals in 2017 (OR 0.30) did not reproduce that specific split with the same statistical clarity on the larger 2021 sample.

This distinction matters practically: one should no longer claim with full confidence that "vitamin D only helps people with a deficiency" — that's a simplification better supported by the 2017 data than by the 2021 data. A more precise statement, consistent with current evidence, is: the protective effect is best documented with daily dosing in the 400-1000 IU range, regardless of whether a person had a baseline deficiency, although people with a deficiency likely still see at least as large a benefit.

One of the most common questions about any supplementation is safety, especially with regular, long-term use. The 2017 meta-analysis checked this directly: the analysis of serious adverse events found no increased risk in the supplemented group versus placebo (OR 0.98; 95% CI 0.80-1.20) — a result statistically indistinguishable from no effect, which is reassuring from a safety standpoint.

Few topics come as close to the popular belief while still diverging so much on precision as vitamin D and colds. Vitamin D really does reduce respiratory infection risk — that's not a myth. The problem lies in how many people take it: in the form of occasional, large doses that, according to both meta-analyses described here, have negligible effectiveness in this specific context. The convenient, infrequent-dose model popular in supplement marketing is convenient for the user, but not necessarily effective for the goal of preventing infections.

It's also worth appreciating that both studies come largely from the same research group, which, in its 2021 update, did not hide the fact that one of its earlier, appealing conclusions (a stronger effect in deficient people) weakened in a larger sample. That's a rare and valuable example of scientific honesty worth factoring into how credible you consider this whole body of results.